X
<

Roche's Drugs, Trials, and FDA Approvals after 1H17

PART:
1 2 3 4 5 6 7 8 9 10 11
Part 9
Roche's Drugs, Trials, and FDA Approvals after 1H17 PART 9 OF 11

Perjeta Could Drive Roche’s Long-Term Growth

APHINITY trial

In June 2017, Roche (RHHBY) presented the results from the Phase 3 APHINITY trial. Roche conducted it to evaluate the safety and efficacy of Perjeta, Herceptin, and chemotherapy combination treatment for individuals with operable HER2 (human epidermal growth factor receptor 2) positive early breast cancer (or eBC).

Perjeta Could Drive Roche’s Long-Term Growth

Interested in RHHBY? Don't miss the next report.

Receive e-mail alerts for new research on RHHBY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Results from APHINITY trial

In the Phase 3 APHINITY trial, Perjeta, Herceptin, and the chemotherapy combination substantially diminished the risk of breast cancer recurrence or death by 19.0% in individuals with HER2 positive eBC versus Herceptin and chemotherapy alone treatment.

At three years, the Phase 3 APHINITY trial demonstrated that 94.1% of the patients on a Perjeta-based triple regimen didn’t have a recurrence of breast cancer compared to 93.1% of patients on the Herceptin and chemotherapy alone regimen.

At a median follow-up of 45.4 months, individuals with lymph node–positive or hormone receptor negative disease demonstrated a greater reduction in risk of invasive breast cancer recurrence when treated with a triple regimen consisting of Perjeta, Herceptin, and chemotherapy. In the APHINITY trial, at three years, 92.0% of the patients on a Perjeta triple regimen with lymph node–positive disease didn’t show any recurrence of breast cancer compared to 90.2% of patients treated with Herceptin and chemotherapy alone. Overall, the APHINITY trial confirmed the clinical benefit of a Perjeta-based triple regimen over the present standard of care. The success in the clinical trial will help in label expansion and could strengthen the marketing capabilities of Perjeta.

Roche’s peers in the oncology drugs market include Novartis (NVS), Amgen (AMGN), AbbVie (ABBV), AstraZeneca, Bristol-Myers Squibb, Pfizer, and others. Growth in sales of Roche’s oncology portfolio could boost the share price of the Vanguard FTSE Developed Markets ETF (VEA). Roche makes up ~0.84% of VEA’s total portfolio holdings.

X

Please select a profession that best describes you: